ACE Inhibition and Vascular Protection in HypertensionLüSCHER, Thomas F.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, 38 p.Conference Proceedings

Modulation of endothelial function in cardiovascular disease: a potential role for nifedipineLüSCHER, Thomas F.Drugs (Basel). 1997, Vol 53, issn 0012-6667, 49 p., SUP1Serial Issue

Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies? : Treatment of Atherosclerosis as an Inflammatory DiseaseKLINGENBERG, Roland; LÜSCHER, Thomas F.Current pharmaceutical design (Print). 2012, Vol 18, Num 28, pp 4358-4369, issn 1381-6128, 12 p.Article

Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugsLÜSCHER, Thomas F; BARTON, Matthias.Circulation (New York, N.Y.). 2000, Vol 102, Num 19, pp 2434-2440, issn 0009-7322Article

Haemodynamics of the vessel wallLüSCHER, Thomas F; KUTRYK, M.Seminars in interventional cardiology. 1998, Vol 3, Num 1, issn 1084-2764, 51 p.Serial Issue

Endothelial function : General considerationsHALLER, H.Drugs (Basel). 1997, Vol 53, pp 1-10, issn 0012-6667, SUP1Article

Multiple postpartal coronary artery dissections and fibromuscular renal artery dysplasiaSCHULER, Pia K; LÜSCHER, Thomas F; KUCHER, Nils et al.European heart journal. 2008, Vol 29, Num 22, pp 2825-2825, issn 0195-668X, 1 p.Article

Pharmacological mechanisms of clinically favorable properties of a selective β₁-Adrenoceptor antagonist, nebivololKUROEDOV, Alexey; COSENTINO, Francesco; LÜSCHER, Thomas F et al.Cardiovascular drug reviews (Print). 2004, Vol 22, Num 3, pp 155-168, issn 0897-5957, 14 p.Article

ET_A receptors mediate vasoconstriction of large conduit arteries during reduced flow in humansSPIEKER, Lukas E; LÜSCHER, Thomas F; NOLL, Georg et al.Journal of cardiovascular pharmacology. 2003, Vol 42, Num 3, pp 315-318, issn 0160-2446, 4 p.Article

Tissue factor in cardiovascular diseases : Molecular mechanisms and clinical implicationsSTEFFEL, Jan; LÜSCHER, Thomas F; TANNER, Felix C et al.Circulation (New York, N.Y.). 2006, Vol 113, Num 5, pp 722-731, issn 0009-7322, 10 p.Article

Unexplored territories with calcium channel blockers: potential for the futureSEVER, Peter S; OPARIL, Suzanne; LüSCHER, Thomas F et al.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 33, Num 2, 26 p.Conference Proceedings

Efficacy and safety of spirapril in mild-to-moderate hypertensionHAYDUK, K; KRAUL, H.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, pp S19-S23Conference Paper

Matching the Risk: CAD Therapy on TimeWILLICH, Stefan N; LüSCHER, Thomas F.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, 36 p.Conference Proceedings

From endothelial dysfunction to cardiovascular diseaseLüSCHER, Thomas F.Journal of cardiovascular pharmacology. Supplement. 1998, Vol 32, Num 3, 82 p.Conference Proceedings

Role of nitrates for the therapy of coronary artery disease patients in the years beyond 2000DARIUS, H.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, pp S15-S20Conference Paper

Circadian variation in cardiovascular events and implications for therapy?MULCAHY, D.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 2, pp S3-S8Conference Paper

Positron emission tomography to assess the haemodynamics of the coronary circulationCAMICI, P. G.Seminars in interventional cardiology. 1998, Vol 3, Num 1, pp 31-38, issn 1084-2764Article

Moving from impact to influence: measurement and the changing role of medical journalsNALLAMOTHU, Brahmajee K; LUSCHER, Thomas F.European heart journal. 2012, Vol 33, Num 23, pp 2892-2896, issn 0195-668X, 5 p.Article

Endothelial nitric oxide synthase : Host defense enzyme of the endothelium?RABELINK, Ton J; LUSCHER, Thomas F.Arteriosclerosis, thrombosis, and vascular biology. 2006, Vol 26, Num 2, pp 267-271, issn 1079-5642, 5 p.Article

Clinical experience with spirapril in human hypertensionSCHMIDT, J; KRAUL, H.Journal of cardiovascular pharmacology. Supplement. 1999, Vol 34, Num 1, pp S25-S30Conference Paper

Coronary endothelial function in health and diseaseBURNETT, J. C.Drugs (Basel). 1997, Vol 53, pp 20-29, issn 0012-6667, SUP1Article

Endothelin in atherosclerosis : Importance of risk factors and therapeutic implicationsD'USCIO, Livius V; BARTON, Matthias; SHAW, Sidney et al.Journal of cardiovascular pharmacology. Supplement. 2000, Vol 35, Num 2, pp S55-S59Conference Paper

Current strategies and perspectives for correcting endothelial dysfunction in atherosclerosisSPIEKER, Lukas E; LÜSCHER, Thomas F; NOLL, Georg et al.Journal of cardiovascular pharmacology. Supplement. 2001, Vol 38, Num 2, pp S35-S41Conference Paper

Endothelin and cardiac arrhythmias : do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?DURU, Firat; BARTON, Matthias; LÜSCHER, Thomas F et al.Cardiovascular research. 2001, Vol 49, Num 2, pp 272-280, issn 0008-6363Article

High dose lisinopril in heart failure: Economic considerationsESS, Silvia M; LÜSCHER, Thomas F; SZUCS, Thomas D et al.Cardiovascular drugs and therapy. 2002, Vol 16, Num 4, pp 365-371, issn 0920-3206, 7 p.Article